Liquidia Technologies (LQDA)
NASDAQ:LQDA
Want to see LQDA full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.79Last Year’s EPS
-0.49Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum: rapid revenue and profitability growth, expanding market share, growing prescription breadth and depth, and a well-funded clinical pipeline. Primary risks cited were legal uncertainty, the need for continued market education (especially in PH-ILD and community settings), dosing convenience considerations (addressable by L606), and timing of broader indication studies. Overall, positives substantially outweigh the challenges described.Company Guidance
Strong Sequential Revenue Growth
Net product sales of YUTREPIA were $129.9M in Q1 2026, up from $90.1M in Q4 2025, representing 44% sequential growth and contributing to an annualized net revenue run rate exceeding $0.5B within one year of launch.
Significant Profitability Improvement
Company reported net income of approximately $52.9M in Q1 2026 versus $14.6M in Q4 2025 (≈+262%), and non-GAAP adjusted EBITDA of ~$71.2M versus $27.3M (≈+161%), marking the third consecutive profitable quarter.
Cash and Balance Sheet Expansion
Cash and cash equivalents ended the quarter at ~$222.8M, an increase of $32.1M from year-end, supporting self-funded investment in manufacturing and clinical programs.
Rapid Market Share and Adoption Gains
Inhaled prostacyclin market share progressed from ~10% (Q3) to >16% (Q4) to almost 23% (Q1), while the overall inhaled market grew ~5% in Q4 and Q1 and Liquidia captured essentially all of that market growth.
Breadth and Depth of Prescriptions
Since launch: ~4,500 unique patient prescriptions, ~3,750 patients started on therapy, ~980 prescribing physicians; number of physicians prescribing YUTREPIA to ≥5 patients increased 25% to ~270 since end of February, indicating repeat adoption and deeper prescribing patterns.
Robust Clinical and Pipeline Progress
Recruitment started for ASCENT Cohort B (transitions from Tyvaso DPI), active screening for pivotal Phase III RESPIRE study of L606 (twice-daily treprostinil liposome), and plans to advance studies into IPF, PPF, PH-COPD and scleroderma-associated Raynaud's — all funded from operating cash flow.
Clear Commercial Strategy and Guidance
Management reiterated line of sight to at least $1B net revenue in 2027, continuing sales force expansion to penetrate community prescribers and build awareness of PH-ILD and other indications.
LQDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LQDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | $42.30 | $53.13 | +25.60% |
Mar 05, 2026 | $34.38 | $34.52 | +0.41% |
Nov 03, 2025 | $24.36 | $25.22 | +3.53% |
Aug 12, 2025 | $21.20 | $24.10 | +13.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Liquidia Technologies (LQDA) report earnings?
Liquidia Technologies (LQDA) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is Liquidia Technologies (LQDA) earnings time?
Liquidia Technologies (LQDA) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LQDA EPS forecast?
LQDA EPS forecast for the fiscal quarter 2026 (Q2) is 0.79.